Vorinostat induced cellular stress disrupts the p38 mitogen activated protein kinase and extracellular signal regulated kinase pathways leading to apoptosis in Waldenström macroglobulinemia cells

Leukemia and Lymphoma

Volumn 52, Issue 9, 2011, Pages 1777-1786

  Sun, Jenny Y ^a   Tseng, Hsiuyi ^a   Xu, Lian ^a   Hunter, Zachary ^a   Ciccarelli, Bryan ^a   Fulciniti, Mariateresa ^a   Zhu, Bangmin ^a   Maghsoudi, Kaveh ^b   Yang, Guang ^a   Gong, Ping ^a   Zhou, Yangsheng ^a   Liu, Xia ^a   Munshi, Nikhil C ^a,c   Patterson, Christopher J ^a   Treon, Steven P ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

cell lines and animal models; chemotherapeutic approaches; lymphocytes; Lymphoma and Hodgkin disease

Indexed keywords

BORTEZOMIB; CASPASE 7; HISTONE DEACETYLASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; VORINOSTAT;

APOPTOSIS; ARTICLE; CELL STRESS; CYTOTOXICITY; DOWN REGULATION; DRUG ACTIVITY; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TUMOR CELL; UPREGULATION; WALDENSTROEM MACROGLOBULINEMIA;

APOPTOSIS; BORONIC ACIDS; CASPASES; CELL LINE; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRAZINES; STRESS, PHYSIOLOGICAL; WALDENSTROM MACROGLOBULINEMIA;

EID: 80052062787     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.577850     Document Type: Article

References (47)

1. Dimopoulos MA, Kyle RA, Anagnostopoulos A, et al. Diagnosis and management of Waldenstrom's macroglobuli-nemia. J Clin Oncol 2005;23:1564-1577.
2. Treon SP, Hatjiharissi E, Merlini G. Waldenstrom's macro-globlinemia/ lymphoplasmacytic lymphoma. Cancer Treat Res 2008;142:211-242.
3. Hatjiharissi E, Mitsiades CS, Ciccarelli BT, et al. Comprehensive molecular characterization of malignant and micro-enviromental cells in Waldenstrom's macroglobulinemia by gene expression profiling. Blood 2007;110(Suppl. 1): Abstract 3174.
4. Eot-Houllier G, Fulcrand G, Magnaghi-Jaulin L, et al. Histone deacetylase inhibitors and genomic instability. Cancer Lett 2009;274:169-176.
5. Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002;1:287-299. (Pubitemid 37361445)
6. Dai Y, Rahmani M, Dent P, et al. Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation. Mol Cell Biol 2005;25:5429-5444. (Pubitemid 40853579)
7. Finnin MS, Donigian JR, Cohen A, et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 1999;401:188-193. (Pubitemid 29436325)
8. Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 2000;92:1210-1216. (Pubitemid 30627729)
9. Richon VM, Sandhoff TW, Rifkind RA, et al. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 2000;97:10014-10019.
10. Ruefli AA, Ausserlechner MJ, Bernhard D, et al. The histone deacetylase inhibitor and chemotherapeutic agent suberoylani-lide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci USA 2001;98:10833-10838. (Pubitemid 32878706)
11. Rosato RR, Grant S. Histone deacetylase inhibitors: insights into mechanisms of lethality. Expert Opin Ther Targets 2005;9:809-824. (Pubitemid 41131680)
12. Dokmanovic M, Marks PA. Prospects: histone deacetylase inhibitors. J Cell Biochem 2005;96:293-304. (Pubitemid 41437862)
13. Dubrez-Daloz L, Dupoux A, Cartier J. IAPs: more than just inhibitors of apoptosis proteins. Cell Cycle 2008;7:1036-1046.
14. Salvesen GS, Duckett CS. IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol 2002;3:401-410. (Pubitemid 34685698)
15. Perrelet D, Ferri A, Liston P, et al. IAPs are essential for GDNF-mediated neuroprotective effects in injured motor neurons in vivo. Nat Cell Biol 2002;4:175-179. (Pubitemid 34141486)
16. Potts MB, Vaughn AE, McDonough H, et al. Reduced Apaf-1 levels in cardiomyocytes engage strict regulation of apoptosis by endogenous XIAP. J Cell Biol 2005;171:925-930. (Pubitemid 41815824)
17. Conte D, Holcik M, Lefebvre CA, et al. Inhibitor of apoptosis protein cIAP2 is essential for lipopolysaccharide-induced macrophage survival. Mol Cell Biol 2006;26:699-708. (Pubitemid 43090921)
18. Warnakulasuriyarachchi D, Cerquozzi S, Cheung HH, et al. Translational induction of the inhibitor of apoptosis protein HIAP2 during endoplasmic reticulum stress attenuates cell death and is mediated via an inducible internal ribosome entry site element. J Biol Chem 2004;279:17148-17157. (Pubitemid 38560471)
19. Lewis SM, Holcik M. IRES in distress: translational regulation of the inhibitor of apoptosis proteins XIAP and HIAP2 during cell stress. Cell Death Differ 2005;12:547-553. (Pubitemid 40767158)
20. Warnakulasuriyarachchi D, Ungureanu NH, Holcik M. The translation of an antiapoptotic protein HIAP2 is regulated by an upstream open reading frame. Cell Death Differ 2003; 10:899-904. (Pubitemid 36939700)
21. Hamanaka RB, Bobrovnikova-Marjon E, Ji X, et al. PERK-dependent regulation of IAP translation during ER stress. Oncogene 2009;28:910-920.
22. Zweifach A, Lewis SA. Characterization of a partially degraded Na+ channel from urinary tract epithelium. J Membr Biol 1988;101:49-56.
23. Hunter T. Oncoprotein networks. Cell 1997;88:333-346. (Pubitemid 27131375)
24. Milella M, Kornblau SM, Estrov Z, et al. Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest 2001;108:851-859. (Pubitemid 32880294)
25. Lee ER, McCool KW, Murdoch FE, et al. Dynamic changes in histone H3 phosphoacetylation during early embryonic stem cell differentiation are directly mediated by mitogen-and stress-activated protein kinase 1 via activation of MAPK pathways. J Biol Chem 2006;281:21162-21172. (Pubitemid 44115456)
26. Lane SW, Scadden DT, Gilliland DG. The leukemic stem cell niche: current concepts and therapeutic opportunities. Blood 2009;114:1150-1157.
27. Chen CI, Kouroukis CT, White D, et al. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macro-globulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1570-1575. (Pubitemid 46733084)
28. Dimopoulos MA, Gertz MA, Kastritis E, et al. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. J Clin Oncol 2009;27:120-126.
29. Heider U, vonMetzler I, Kaiser M, et al. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma. Eur J Haematol 2008;80:133-142.
30. Mitsiades CS, Hayden PJ, Anderson KC, et al. From the bench to the bedside: emerging new treatments in multiple myeloma. Best Pract Res Clin Haematol 2007;20:797-816. (Pubitemid 350215385)
31. Richardson P, Mitsiades C, Schlossman R, et al. The treatment of relapsed and refractory multiple myeloma. Hematology Am Soc Hematol Educ Program 2007:317-323.
32. DitzelSantos D, Ho AW, Tournilhac O, et al. Establishment of BCWM.1 cell line for Waldenstrom's macroglobulinemia with productive in vivo engraftment in SCID-hu mice. Exp Hematol 2007;35:1366-1375. (Pubitemid 47302595)
33. Sun JY, Xu L, Tseng H, et al. Histone deacetylase inhibitors demonstrate significant preclinical activity as single agents, and in combination with bortezomib in Waldenstrom's macro-globulinemia. Clin Lymphoma Myeloma Leuk 2011;11:152-156.
34. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006;58:621-681.
35. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002;20:4420-4427. (Pubitemid 35334752)
36. Pei XY, Dai Y, Grant S. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res 2004;10:3839-3852. (Pubitemid 38697620)
37. Catley L, Weisberg E, Kiziltepe T, et al. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyper-acetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood 2006;108:3441-3449.
38. Yuan J, Horvitz HR. A first insight into the molecular mechanisms of apoptosis. Cell 2004;116:S53-S56, 1 p following S59.
39. Guicciardi ME, Mott JL, Bronk SF, et al. Cellular inhibitor of apoptosis 1 (cIAP-1) degradation by caspase 8 during TNF-related apoptosis-inducing ligand (TRAIL)-induced apopto-sis. Exp Cell Res 2011;317:107-116.
40. Doyle BT, O'Neill AJ, Newsholme P, et al. The loss of IAP expression during HL-60 cell differentiation is caspase-independent. J Leukoc Biol 2002;71:247-254.
41. Mitsiades N, Mitsiades CS, Richardson PG, et al. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 2003;101:4055-4062. (Pubitemid 36857886)
42. Yu C, Rahmani M, Conrad D, et al. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood 2003;102:3765-3774. (Pubitemid 37409399)
43. Zhang QL, Wang L, Zhang YW, et al. The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis. Leukemia 2009;23:1507-1514.
44. Orlowski RZ, Small GW, Shi YY. Evidence that inhibition of p44/42 mitogen-activated protein kinase signaling is a factor in proteasome inhibitor-mediated apoptosis. J Biol Chem 2002; 277:27864-27871. (Pubitemid 34966732)
45. Lin H, Chen C, Li X, et al. Activation of the MEK/MAPK pathway is involved in bryostatin1-induced monocytic differ-enciation and up-regulation of X-linked inhibitor of apoptosis protein. Exp Cell Res 2002;272:192-198. (Pubitemid 34920687)
46. Vrana JA, Grant S. Synergistic induction of apoptosis in human leukemia cells (U937) exposed to bryostatin 1 and the proteasome inhibitor lactacystin involves dysregulation of the PKC/MAPK cascade. Blood 2001;97:2105-2114. (Pubitemid 32239093)
47. Leleu X, Jia X, Runnels J, et al. The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia. Blood 2007;110:4417-4426. (Pubitemid 351377808)